T.R. Eijgenraam, BSc

No picture available
E-mail:
t.r.eijgenraam umcg.nl

Research

Publications
  1. Generation and validation of a mouse model of the phospholamban p.Arg14del mutation

    Eijgenraam, T., Sillje, H. & de Boer, R., 2018, In : European Journal of Heart Failure. 20, Suppl. S1, p. 197 1 p., 854.

    Research output: Contribution to journalMeeting AbstractAcademic

  2. A novel phospholamban p.Arg14del cardiomyopathy mouse line treated with heart failure medication

    Eijgenraam, T. R., Schouten, E. M., Gehlken, A. C. D. I., Dokter, M. M., Sillje, H. H. W. & De Boer, R. A., May-2019, In : European Journal of Heart Failure. 21, Suppl. S1, p. 477 1 p., P1879.

    Research output: Contribution to journalMeeting AbstractAcademic

  3. The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy

    Eijgenraam, T. R., Boukens, B. J., Boogerd, C. J., Schouten, E. M., van de Kolk, C. W. A., Stege, N. M., Te Rijdt, W. P., Hoorntje, E. T., van der Zwaag, P. A., van Rooij, E., van Tintelen, J. P., van den Berg, M. P., van der Meer, P., van der Velden, J., Silljé, H. H. W. & de Boer, R. A., 17-Jun-2020, In : Scientific Reports. 10, 1, 13 p., 9819.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Current understanding of fibrosis in genetic cardiomyopathies

    Eijgenraam, T. R., Silljé, H. H. W. & de Boer, R. A., 23-Sep-2019, In : TRENDS IN CARDIOVASCULAR MEDICINE. 9 p.

    Research output: Contribution to journalReview articleAcademicpeer-review

View all (6) »

ID: 26193396